|
|
|
|
|
Bumetanide: profile and news
Membrane trafficking and the regulation of NKCC2 Feb 9, 2006 Increased Serum Creatinine More Likely when Nesiritide is Combined ... Nov 16, 2005 Alternative renin regulatory pathways and the NKCC1 isoform Nov 8, 2005 An existing diuretic may suppress seizures in newborns 31 Oct 2005 Jan de Vries: Is there an alternative to taking steroids for life? Mar 14, 2005 Jan de Vries: Is there an alternative to taking steroids for life? 14 Mar 2005 Other information Indication For the treatment of edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome Pharmacology Bumetanide, a sulfonamide-type loop diuretic structurally related to furosemide, is used to manage hypertension and edema associated with congestive heart failure, cirrhosis, and renal disease, including the nephrotic syndrome. Bumetanide inhibits sodium reabsorption in the ascending limb of the loop of Henle. Mechanism Of Action Bumetanide interferes with renal cAMP and/or inhibits the sodium-potassium possibly sodium in the ascending loop of Henle, altering electrolyte transfer in the proximal tubule. This results in excretion of sodium, chloride, and water and, hence, leads to diuresis. Drug Category Diuretics; ATC:C03CA02 Brand Names/Synonyms B3023; Bumetanida [Inn-Spanish]; Bumetanide; Bumetanide [Usan:Ban:Inn:Jan]; Bumetanidum [Inn-Latin]; Bumex; Burine; Burinex; CHEMBANK404; EI-168; Fontego; Fordiuran; Lixil; Lunetoron; PF 1593; Segurex; [Inn-Spanish] Dosage Forms TABLET Absorption Not Available Interactions Interactions for Bumetanide: 1. Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered bumetanide in patients to whom aminoglycoside antibiotics are also being given should be avoided, except in life-threatening conditions. 2. Drugs with nephrotoxic potential: There has been no experience on the concurrent use of bumetanide with drugs known to have a nephrotoxic potential. Therefore, the simultaneous administration of these drugs should be avoided. 3. Lithium: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity. 4. Probenecid: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide. This antagonistic effect of probenecid on bu-metanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide. Thus, probenecid should not be administered concurrently with bumetanide. 5. Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity. Concurrent therapy with bumetanide is thus not recommended. 6. Antihypertensives: Bumetanide may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs. 7. Digoxin: Interaction studies in humans have shown no effect on digoxin blood levels. 8. Anticoagulants: Interaction studies in humans have shown bumetanide to have no effect on warfarin metabolism or on plasma prothrombin activity. Chemical IUPAC Name 3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid Chemical Formula C17H20N2O5S Half Life 1 - 1.5 hours Drug Type Approved Drug # Accession No APRD00294 CAS Registry Number 28395-03-1 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |